Cogent Biosciences (NASDAQ: COGT) insider transactions
In the twelve months to 10 November 2026, executives and directors of Cogent Biosciences reported 8 open-market sales of 10,860,152 shares ($383.9m) and 0 open-market purchases, by 6 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 27 August 2026 | Morris Arlene | Director | Option exercise | +41,927 | $5.64 | 41,927 | Form 4 |
| 27 August 2026 | Morris Arlene | Director | Option exercise | +3,583 | $2.52 | 45,510 | Form 4 |
| 27 August 2026 | Morris Arlene | Director | Open-market sale | −42,349 | $37.09 | 3,161 | Form 4 |
| 27 August 2026 | Morris Arlene | Director | Open-market sale | −3,161 | $37.54 | 0 | Form 4 |
| 19 May 2026 | Robbins Andrew R | President and CEO | Gift | −160,000 | — | 497,503 | Form 4 |
| 19 May 2026 | Robbins Andrew R | President and CEO | Gift | +160,000 | — | 160,000 | Form 4 |
| 31 March 2026 | Fairmount Funds Management LLC | Director | Conversion | +7,000,000 | — | 12,503,418 | Form 4 |
| 31 March 2026 | Fairmount Funds Management LLC | Director | Open-market sale | −7,000,000 | $34.66 | 5,503,418 | Form 4 |
| 22 January 2026 | Fairmount Funds Management LLC | Director | Open-market sale | −3,500,000 | $36.40 | 5,503,418 | Form 4 |
| 26 December 2025 | Robinson John Edward | Chief Scientific Officer | Open-market sale | −90,000 | $38.74 | 140,002 | Form 4 |
| 26 December 2025 | Sachs Jessica | Chief Medical Officer | Open-market sale | −82,642 | $38.70 | 133,938 | Form 4 |
| 26 December 2025 | Green John L. | Chief Financial Officer | Open-market sale | −77,000 | $38.68 | 131,834 | Form 4 |
| 26 December 2025 | Kearns Evan | Chief Legal Officer | Open-market sale | −65,000 | $38.70 | 109,398 | Form 4 |
| 17 December 2025 | Green John L. | Chief Financial Officer | Grant or award | +50,000 | — | 53,841 | Form 4 |
| 17 December 2025 | Green John L. | Chief Financial Officer | Grant or award | +300,000 | — | 353,841 | Form 4 |
| 17 December 2025 | Green John L. | Chief Financial Officer | Shares withheld for tax | −145,007 | $39.45 | 208,834 | Form 4 |
| 17 December 2025 | Kearns Evan | Chief Legal Officer | Grant or award | +40,000 | — | 40,000 | Form 4 |
| 17 December 2025 | Kearns Evan | Chief Legal Officer | Grant or award | +260,000 | — | 300,000 | Form 4 |
| 17 December 2025 | Kearns Evan | Chief Legal Officer | Shares withheld for tax | −125,602 | $39.45 | 174,398 | Form 4 |
| 17 December 2025 | Sachs Jessica | Chief Medical Officer | Grant or award | +50,000 | — | 51,296 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Cogent Biosciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.